The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020.
Mike Blake | Reuters
Eli Lilly‘s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities.
This is original news content created by on www.cnbc.com, Newslogic.in or any author at newslogic.in has no rights over this content. This content is auto fetched from the original post, the link to the original post is given below.